Generalized Pustular Psoriasis: Impact Beyond the Skin
Generalized pustular psoriasis (GPP) is not only about the physical symptoms that impact people living with the condition. GPP goes deeper, beyond the skin.
Search
U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)
U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)
Redefining mental health to enable people to thrive
At Boehringer Ingelheim, we aim to develop targeted treatment approaches that address specific symptoms in people living with mental illness.
Importance_of_physical_activity_in_managing_COPD.pdf
Evolving the Unwearable Collection
Boehringer Ingelheim will partner with the Fashion Institute of Technology in New York to introduce a fifth design as part of The Unwearable Collection™
Schizophrenia
Schizophrenia
4 Possible Signs of Diabetes in Cats | Boehringer Ingelheim US
Click here to read more on the possible signs of diabetes in your feline friends, including how to identify and prevent potential symptoms and risks.
Innovation in CNS Disease Research
Innovation in CNS Disease Research
Boehringer Ingelheim and Lilly expand heart failure program for Jardiance with new exercise capacity trials
Boehringer Ingelheim and Lilly expand heart failure program for Jardiance with new exercise capacity trials
SPEVIGO approved for expanded indications in China and the US
FDA approval for the Treatment of Generalized Pustular Psoriasis (GPP) in Adults and Pediatric Patients 12 Years of Age and Older Weighing at Least 40kg
Novel antibody shows potential to transform treatment of rare form of psoriasis
Novel antibody shows potential to transform treatment of rare form of psoriasis
Yankees Legend Bernie Williams and Celebrity Vocal Coach Eric Vetro Harness the Power of Music with Tune In To Lung Health® for Interstitial Lung Disease Awareness
An extension of Boehringer Ingelheim’s Breathless® campaign, Tune In To Lung Health explores how music and breathing may help motivate, inspire, and support people living with interstitial lung disease (ILD) Program resources introduced during September’s
Depression
Depression
Borderline Personality Disorder
Borderline Personality Disorder
GPP
Generalized Pustular Psoriasis (GPP) is a rare, lifelong skin disease, which may be life-threatening if left untreated.
Boehringer Shows Support for Children with Skin Conditions
This year, Boehringer Ingelheim joined campers at Camp Discovery in Millville, PA to demonstrate its support for those facing chronic skin conditions.
The Burdens of Schizophrenia
It can be hard for people living without schizophrenia to realize its burdens. Understanding these challenges can provide insights to help patients in need.
Prioritizing mental health and well-being today and every day
Prioritizing Mental Health and Well-being Today and Everyday
Work life wellness
We provide you with a range of benefits and services, including counselling, exercise classes, social events to help you stay mentally and physically fit.
FDA approves the first treatment option for generalized pustular psoriasis flares in adults
FDA approves the first treatment option for generalized pustular psoriasis flares in adults
New GPP Consensus Statement Released
National Psoriasis Foundation Releases Consensus Statement on Management of Generalized Pustular Psoriasis (GPP)
Hypertension
Hypertension
Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm)
Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm)
Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis
Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis
US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch
US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch